These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23657069)

  • 1. Efficacy of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria requiring transfusions 14 years after a diagnosis in childhood.
    Ueda T; Hayakawa J; Yamanishi M; Maeda M; Fukunaga Y
    J Nippon Med Sch; 2013; 80(2):155-9. PubMed ID: 23657069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
    Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
    Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
    de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
    Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
    Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
    Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hill A; Hillmen P; Richards SJ; Elebute D; Marsh JC; Chan J; Mojcik CF; Rother RP
    Blood; 2005 Oct; 106(7):2559-65. PubMed ID: 15985537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    DeZern AE; Dorr D; Brodsky RA
    Eur J Haematol; 2013 Jan; 90(1):16-24. PubMed ID: 23046169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Hill A; Richards SJ; Rother RP; Hillmen P
    Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
    Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
    Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
    Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.